Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperlasia

Annals of Saudi Medicine

Volumn 24, Issue 1, 2004, Pages 21-26

  Tayeb, Mohammed T ^a,b,d   Clark, Caroline ^a   Murray, Graeme I ^a   Sharp, Linda ^a   Haites, Neva E ^a   McLeod, Howard L ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

^c WASHINGTON UNIVERSITY   (United States)

^d NONE   (Saudi Arabia)

Author keywords

Androgen receptor; Benign prostate hyperplasia; Instability; Polymorphism; Prostate cancer; Triplet repeat instability

Indexed keywords

ANDROGEN RECEPTOR; GLYCINE DERIVATIVE; POLYGLUTAMINE; POLYGLYCINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXON; GENETIC POLYMORPHISM; GENETIC STABILITY; HUMAN; HUMAN TISSUE; MALE; MOLECULAR SIZE; MOSAICISM; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEQUENCE ANALYSIS; SOMATIC MUTATION; TRINUCLEOTIDE REPEAT;

EID: 1042304230     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2004.21     Document Type: Article

References (44)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. Ca Cancer J Clin. 1996; 46: 5-27.
2. Prior T, Waxman J. Localised prostate cancer: can we do better? There have been some advances in local control, but little impact on survival. BMJ. 2000; 320: 69-70.
3. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, The CZ, Stamey T. Family history and prostate cancer risk in black, white, and Asian men in the United State and Canada. Am J Epidemiol 1995; 141: 732-740.
4. Wingo PA, Bolden S, Tong T, Parker SL, Martin LM, Heath CW. Cancer statistics for African Americans, 1996. CA Cancer J Clin. 1996; 46:113-125.
5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343: 78-85.
6. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate. 1990;16:39-48.
7. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992; 70: 291-301.
8. Armenian HK, Lilienfeld AM, Diamond EL, Bross ID. Relation between benign prostatic hyperplasia and cancer of the prostate. Lancet. 1974; 2: 115-117.
9. Schuman LM, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R. Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat Rep. 1977; 61:181-186.
10. Chen TT, Heidelberger C. In vitro malignant transformation of cells derid from mouse prostate in the presence of 3-methylcholanthrene. J Natl Cancer Inst. 1969; 42:915-925.
11. Fraley EE, Ecker S, Vincent MM. Spontaneous in vitro neoplastic transformation of adult human prostatic epithelium. Science. 1970; 170: 540-542.
12. Franks LM, Wilson PD. "Spontaneous" neoplastic transformation in vitro: the ultrastructure of the tissue culture cell. Eur J Cancer. 1970. 6: 517-523.
13. Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French FS, Willard HF. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet. 1989; 44: 264-269.
14. Kuiper GG, Faber PW, van Rooij HC, van der Korput JA, Ris-Stalpers C, Klaassen P, Trapman J, Brinkmann AO. Structural organization of the human androgen receptor gene. J Mol Endocrinol. 1989; 2: R1-R4.
15. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22: 3181-3186.
16. Choong CS, Kemppainen JA, Zhou ZX, Wilson EM. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol Endocrinol. 1996; 10:1527-1537.
17. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens H, Kantoff PW. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci. USA 1997; 94: 3320-3323.
18. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantodosi S, Barrack ER. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res. 1997; 3: 1599-1608.
19. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997; 89: 166-170.
20. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA, Ostrander EA. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 1997; 57: 1194-1198.
21. Kantoff PW, Giovannucci E, Brown M. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. Biochem Biophys Acta. 1998; 1378: C1-C5.
22. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2000; 60: 5111-5116.
23. Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol. 2000; 164: 567-572.
24. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer. 1999; 81: 672-676.
25. Beilin J, Harewood L, Frydenberg M, Mameghan H, Martyres RF, Farish SJ, Yue C, Deam DR, Byron KA, Zajac JD. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer. 2001; 92:941-949.
26. Correa-Cerro L, Wohr G, Haussler J, Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P, Just W, Paiss T, Cantu JM, Vogel W. (CAG)n CAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet. 1999; 7:357-362.
27. Edwards SM, Badzioch MD, Minter R, Hamoudi R, Collins N, Ardern-Jones A, Dowe A, Osborne S, Kelly J, Shearer R, Easton DF, Saunders GF, Dearnaley DP, Eeles RA. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer. 1999; 84: 458-465.
28. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol. 1999; 189: 559-563.
29. Lange EM, Chen H, Brierley K, Livermore H, Wojno KJ, Langefeld CD, Lange K, Cooney KA. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9: 439-442.
30. Giovannucci E, Platz EA, Stampfer MJ, Chan A, Krithivas K, Kawachi I, Willett WC, Kantoff PW. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology. 1999; 53: 121-125.
31. Giovannucci E, Stampfer MJ, Chan A, Krithivas K, Gann PH, Hennekens CH, Kantoff PW. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate. 1999; 39: 130-134.
32. Mitsumori K, Terai A, Oka H, Segawa T, Ogura K, Yoshida O, Ogawa O. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate. 1999; 41: 253-257.
33. Bousema JT, Bussemakers MJ, van Houwelingen KP, Debruyne FM, Verbeek AL, de La Rosette JJ, Kiemeney LA. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia. Eur Urol. 2000; 37: 234-238.
34. Suzuki H, Akakura K, Komiya A, Ueda T, Imamoto T, Furuya Y, Ichikawa T, Watanabe M, Shiraishi T, Ito H. CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate. 2002; 51:219-224.
35. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. Microsatellite mutation (CAG24->18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun. 1994; 198: 74-80.
36. Terrell RB, Wille AH, Cheville JC, Nystuen AM, Cohen MB, Sheffield VC. Microsatellite instability in adenocarcinoma of the prostate. Am J Pathol. 1995; 147: 799-805.
37. Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN, McLeod HL CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep. 2002; 9: 653-655.
38. Frank TS, Savoboda-Newman SM, His ED. Comparison of methods for extracting DNA from formalin-fixed paraffin sections for Nonisotopic PCR. Diagn Mol Pathol. 1996; 5: 220-224.
39. Curran S, McKay JA, McLeod HL, Murray GI. Laser Capture Pathology. Mol Pathol. 2000; 53: 64-68.
40. Norremolle A, Riess O, Epplen JT, Fenger K, Hasholt L, Sorensen SA. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet. 1993; 2: 1475-1476.
41. Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet. 1997;15:197-200.
42. Tanaka F, Reeves MF, Ito Y, Matsumoto M, Li M, Miwa S, Inukai A, Yamamoto M, Doyu M, Yoshida M, Hashizume Y, Terao S, Mitsuma T, Sobue G. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor-gene expression level. Am J Hum Genet. 1999; 65: 966-973.
43. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia. Submitted.
44. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer. 2003; 88:928-932.